CADTH Provisional Funding Algorithms

1. About Provisional Funding Algorithms 

The provisional algorithm process is used to provide advice to drug programs when they have indicated that there is need to establish an appropriate place in therapy for new oncology drugs relative to alternative treatments that are currently reimbursed by the drug programs. The process ascertains the impact of new therapies on the sequencing of treatments for the purposes of reimbursement (e.g., should reimbursing a new drug result in a shift or a displacement of other available treatments). While broad in scope, funding algorithms are focused on reimbursement decision-making; they are not treatment algorithms or guidelines and do not fully detail the clinical management of cancer patients.

CADTH will initiate the development of a provisional algorithm in the following instances:

  • following issuance of a recommendation in favour of the reimbursement of a drug with the potential to impact the existing funding algorithm for the indication of interest; or
  • when new evidence that may disrupt the sequencing of drugs is identified; and
  • when the participating drug programs indicate that a provisional algorithm is required for implementation purposes.

Please review the Procedures for CADTH Reimbursement Reviews for complete details.

2. Contribute

CADTH issues a call for stakeholder input at the time the provisional algorithm project is initiated and seeks stakeholder feedback on the draft provisional algorithm. The following stakeholders are eligible to contribute: patient groups, clinician groups, the participating drug programs, and drug manufacturers whose products may be directly impacted by the provisional algorithm.

Open calls for input and feedback are highlighted in the CADTH Weekly Update and instructions for contributing are provided below.

2.1 Initial Input on a Provisional Funding Algorithm Project

To provide initial input at the outset of the provisional algorithm project:

  • Locate the webpage for provisional algorithm project of interest from the CADTH Weekly Update or the list of current opportunities for input and feedback.
  • Review the proposed project scope for the provisional algorithm.
  • Download the stakeholder input template.
  • Complete the template by the deadline specified on the project webpage.
  • Send the completed template by clicking Submit Feedback on the project webpage.

2.2 Stakeholder Feedback on a Draft Provisional Funding Algorithm

To provide stakeholder feedback on a draft provisional algorithm report:

  • Locate the webpage for provisional algorithm project of interest from the CADTH Weekly Update or the list of current opportunities for input and feedback.
  • Review the draft provisional funding algorithm report.
  • Download the stakeholder feedback template.
  • Complete the template by the deadline specified on the project webpage.
  • Send the completed template by Submit Feedback on the project webpage.

3. CADTH Provisional Funding Algorithm Projects

Updates on CADTH provisional funding algorithms are posted to this page. Reports are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.

Tumour Type

Therapeutic Area

Project Number

Project Status

Date Final Report Posted

Breast HER2-positive metastatic breast cancer PH0006-000 Complete April 12, 2022
Breast HER2-positive metastatic breast cancer PH0016-000 Complete January 13, 2023
Breast HR+ HER2- Breast Cancer PH0018-000 Complete March 8, 2023
Breast HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer PH0033-000 In progress  
Breast Triple Negative Breast Cancer PH0024-000 Complete June 14, 2023
Gastrointestinal Unresectable Hepatocellular Carcinoma PH0036-000 Open for Stakeholder Feedback  
Gastrointestinal Unresectable Hepatocellular Carcinoma PH0003-000 Complete April 21, 2021
Gastrointestinal Human Epidermal Growth Factor Receptor 2(HER2) Negative Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer PH0010-000 Complete June 21, 2022
Gastrointestinal Colon Cancer PH0005-000 Complete November 12, 2021
Genitourinary Metastatic Urothelial Carcinoma PH0008-000 Complete March 28, 2022
Genitourinary Metastatic Urothelial Carcinoma PH0017-000 Complete January 11, 2023
Genitourinary Renal Cell Carcinoma PH0013-000 Complete September 6, 2022
Genitourinary Renal Cell Carcinoma PH0019-000 Complete January 11, 2023
Genitourinary Prostate cancer PH0023-000 Complete May 3, 2023
Genitourinary Prostate Cancer PH0034-000 Complete October 27, 2023
Leukemia Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive PH0030-000 Complete June 28, 2023
Leukemia Adult B-cell precursor Acute Lymphoblastic Leukemia, Philadelphia chromosome negative PH0002-000 Complete February 24, 2021
Leukemia Chronic Lymphocytic Leukemia PH0004-000 Complete May 18, 2021
Leukemia Chronic Lymphocytic Leukemia PH0035-000 Complete October 27, 2023
Lung Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer PH0009-000 Complete May 24, 2022
Lung NSCLC without actionable oncogenic alterations PH0012-000 Complete August 5, 2022
Lung NSCLC without actionable oncogenic alterations PH0015-000 Complete December 1, 2022
Lung RET-fusion positive NSCLC PH0020-000 Withdrawn -
Lung RET fusion-positive non-small cell lung cancer PH0026-000 Complete June 1, 2023
Lung Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations PH0028-000 Complete June 1, 2023
Lung Non-Small Cell Lung Cancer without actionable oncogenic alterations PH0029-000 Complete August 10, 2023
Lymphoma Adult Classical Hodgkin Lymphoma PH0007-000 Complete February 2, 2022
Lymphoma Large B-Cell Lymphoma PH0027-000 Complete April 11, 2023
Myeloma Multiple Myeloma PH0031-000 Complete July 27, 2023
Myeloma Multiple Myeloma PH0011-000 Complete May 25, 2022
Myeloma Multiple Myeloma PH0014-000 Complete November 15, 2022
Other Differentiated Thyroid Carcinoma PH0021-000 Complete February 06, 2023
Skin & Melanoma Melanoma PH0022-000 Complete February 06, 2023